Progesterone increases apoptosis and inversely decreases autophagy in human hepatoma HA22T/VGH cells treated with epirubicin

Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Chang, Wen Tsan ^a,b   Cheng, Hsiao Ling ^a   Hsieh, Bau Shan ^a   Chiu, Chien Chih ^c   Lee, King Teh ^a,b   Chang, Kee Lung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; CASPASE 3; EPIRUBICIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PROGESTERONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; ANTINEOPLASTIC ANTIBIOTIC; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ACIDIC VESICULAR ORGANELLE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ORGANELLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; DRUG EFFECTS; GENETICS; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; EPIRUBICIN; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROGESTERONE; RNA, MESSENGER;

EID: 84902131752     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/567148     Document Type: Article

References (48)

1. El-Serag H. B., Hepatocellular carcinoma. New England Journal of Medicine 2011 365 12 1118 1127 2-s2.0-80053088189 10.1056/NEJMra1001683
2. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
3. Bruix J., Sherman M., American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011 53 3 1020 1022 2-s2.0-79952231921 10.1002/hep.24199
4. Omata M., Lesmana L. A., Tateishi R., Chen P. J., Lin S. M., Yoshida H., Kudo M., Lee J. M., Choi B. I., Poon R. T. P., Shiina S., Cheng A. L., Jia J. D., Obi S., Han K. H., Jafri W., Chow P., Lim S. G., Chawla Y. K., Budihusodo U., Gani R. A., Lesmana C. R., Putranto T. A., Liaw Y. F., Sarin S. K., Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatology International 2010 4 2 439 474 2-s2.0-77955499020 10.1007/s12072-010-9165-7
5. Chang W. T., Kao W. Y., Chau G. Y., Su C. W., Lei H. J., Wu J. C., Hsia C. Y., Lui W. Y., King K. L., Lee S. D., Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery 2012 152 5 809 820 10.1016/j.surg.2012.03. 024
6. Kim S. J., Seo H. Y., Choi J. G., Sul H. R., Sung H. J., Park K. H., Choi I. K., Oh S. C., Yoon S. Y., Seo J. H., Choi C. W., Kim B. S., Shin S. W., Kim Y. H., Kim J. S., Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2006 57 4 436 442 2-s2.0-30644468475 10.1007/s00280-005-0067-7 (Pubitemid 43087586)
7. Green T. J., Rochon P. J., Chang S., Ray C. E. Jr, Winston H., Ruef R., Kreidler S. M., Glueck D. H., Shulman B. C., Brown A. C., Durham J., Downstaging disease in patients with hepatocellular carcinoma outside of milan criteria: strategies using drug-eluting bead chemoembolization. Journal of Vascular and Interventional Radiology 2013 24 11 1613 1622 10.1016/j.jvir.2013.07.024
8. Kebieche M., Lakroun Z., Lahouel M., Bouayed J., Meraihi Z., Soulimani R., Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. Experimental and Toxicologic Pathology 2009 61 2 161 167 2-s2.0-61349169589 10.1016/j.etp.2008.06.002
9. Salvatorelli E., Guarnieri S., Menna P., Liberi G., Calafiore A. M., Mariggio M. A., Mordente A., Gianni L., Minotti G., Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition. Journal of Biological Chemistry 2006 281 16 10990 11001 2-s2.0-33744959330 10.1074/jbc.M508343200 (Pubitemid 43855522)
10. Ozkan A., Fişkin K., Epirubicin HCl toxicity in human liver-derived hepatoma G2 cells. Polish Journal of Pharmacology 2004 56 4 435 444 2-s2.0-9744255513 (Pubitemid 39585897)
11. Zhu A. X., Fuchs C. S., Clark J. W., Muzikansky A., Taylor K., Sheehan S., Tam K., Yung E., Kulke M. H., Ryan D. P., A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 2005 10 6 392 398 2-s2.0-22244436300 10.1634/theoncologist.10-6-392 (Pubitemid 40993567)
12. Yeo W., Mok T. S., Zee B., Leung T. W. T., Lai P. B. S., Lau W. Y., Koh J., Mo F. K. F., Yu S. C. H., Chan A. T., Hui P., Ma B., Lam K. C., Ho W. M., Wong H. T., Tang A., Johnson P. J., A randomized phase III study of doxorubicin versus cisplatin/interferon α -2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. Journal of the National Cancer Institute 2005 97 20 1532 1538 2-s2.0-27144557565 10.1093/jnci/dji315 (Pubitemid 41631953)
13. Duvoux C., Kiuchi T., Pestalozzi B., Busuttil R., Miksad R., What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transplantation 2011 17 supplement 2 S147 S158 2-s2.0-80053287635 10.1002/lt.22367
14. Ahn J. H., Lee M., Autophagy-dependent survival of mutant B-Raf melanoma cells selected for resistance to apoptosis induced by inhibitors against oncogenic B-Raf. Biomolecules & Therapeutics 2013 21 2 114 120 10.4062/biomolther.2013.012
15. Yang Z., Klionsky D. J., Mammalian autophagy: core molecular machinery and signaling regulation. Current Opinion in Cell Biology 2010 22 2 124 131 2-s2.0-77951214016 10.1016/j.ceb.2009.11.014
16. Sun W. L., Chen J., Wang Y. P., Zheng H., Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011 7 9 1035 1044 2-s2.0-80052306066 10.4161/auto.7.9.16521
17. Lewin J., Cooper A., Birch B., Progesterone: a novel adjunct to intravesical chemotherapy. BJU International 2002 90 7 736 741 2-s2.0-0036432772 10.1046/j.1464-410X.2002.03013.x (Pubitemid 35356644)
18. Villa E., Ferretti I., Grottola A., Buttafoco P., Buono M. G. D., Giannini F., Manno M., Bertani H., Dugani A., Manenti F., Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. British Journal of Cancer 2001 84 7 881 885 2-s2.0-17744383359 10.1054/bjoc.2000.1534 (Pubitemid 32385828)
19. Giacomin A., Sergio A., Vanin V., Tartaro P., Paccagnella D., Mazzucco M., Farinati F., Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: a prospective randomized trial in the pre-sorafenib era. Hepatology Research 2010 40 2 153 160 2-s2.0-77954379927 10.1111/j.1872-034X.2009.00588.x
20. Hsieh B. S., Huang L. W., Su S. J., Cheng H. L., Hu Y. C., Hung T. C., Chang K. L., Combined arginine and ascorbic acid treatment induces apoptosis in the hepatoma cell line HA22T/VGH and changes in redox status involving the pentose phosphate pathway and reactive oxygen and nitrogen species. Journal of Nutritional Biochemistry 2011 22 3 234 241 2-s2.0-79951675742 10.1016/j.jnutbio.2010.01.009
21. Cheng H. L., Su S. J., Huang L. W., Hsieh B. S., Hu Y. C., Hung T. C., Chang K. L., Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis-involvement of STAT3 and RhoA activation. Molecular Cancer 2010 9, article 126 2-s2.0-77952711940 10.1186/1476-4598-9-126
22. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., Domingo D., Yahalom J., A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Research 2001 61 2 439 444 2-s2.0-0035863399 (Pubitemid 32128593)
23. Hu Y. C., Cheng H. L., Hsieh B. S., Huang L. W., Huang T. C., Chang K. L., Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function. Bone 2012 50 6 1406 1415 10.1016/j.bone.2012.03. 012
24. Huang H. L., Fang L. W., Lu S. P., Chou C. K., Luh T. Y., Lai M. Z., DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 2003 22 50 8168 8177 2-s2.0-0344825072 10.1038/sj.onc.1206979 (Pubitemid 37487307)
25. 2+/ROS-mediated suppression of ERK/c-Fos pathway and activation of p38 MAPK/ATF-2 pathway. Toxicology Letters 2009 191 2-3 140 148 2-s2.0-70449520163 10.1016/j.toxlet. 2009.08.016
26. Ng K. T., Guo D. Y., Cheng Q., Geng W., Ling C. C., Li C. X., Liu X. B., Ma Y. Y., Lo C. M., Poon R. T., Fan S. T., Man K., A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS ONE 2012 7 2 e31655 10.1371/journal.pone.0031655
27. Zhao J., Dong L., Lu B., Wu G., Xu D., Chen J., Li K., Tong X., Dai J., Yao S., Wu M., Guo Y., Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008 135 3 956 968 2-s2.0-51249084799 10.1053/j.gastro.2008.05. 025
28. Cheng X., Shimizu I., Yuan Y., Wei M., Shen M., Huang H., Urata M., Sannomiya K., Fukuno H., Hashimoto-Tamaoki T., Ito S., Effects of estradiol and progesterone on tumor necrosis factor alpha-induced apoptosis in human hepatoma HuH-7 cells. Life Sciences 2006 79 21 1988 1994 2-s2.0-33749516280 10.1016/j.lfs.2006.06.044 (Pubitemid 44528579)
29. Zhang K., Chow P. K. H., The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clinical Cancer Research 2004 10 15 5226 5232 2-s2.0-4143068028 10.1158/1078-0432.CCR-04-0061 (Pubitemid 39099797)
30. Donohue E., Thomas A., Maurer N., The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. Journal of Cancer 2013 4 7 585 596 10.7150/jca.7030
31. Shen J., Zheng H., Ruan J., Fang W., Li A., Tian G., Niu X., Luo S., Zhao P., Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. British Journal of Cancer 2013 109 1 164 171 10.1038/bjc.2013.306
32. Greene L. M., Nolan D. P., Regan-Komito D., Campiani G., Williams D. C., Zisterer D. M., Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells. International Journal of Oncology 2013 43 3 927 935 10.3892/ijo.2013.1989
33. Kang R., Zeh H. J., Lotze M. T., Tang D., The Beclin 1 network regulates autophagy and apoptosis. Cell Death and Differentiation 2011 18 4 571 580 2-s2.0-79952628267 10.1038/cdd.2010.191
34. Lama D., Sankararamakrishnan R., Molecular dynamics simulations of pro-apoptotic BH3 peptide helices in aqueous medium: relationship between helix stability and their binding affinities to the anti-apoptotic protein Bcl- X L. Journal of Computer-Aided Molecular Design 2011 25 5 413 426 2-s2.0-80051693048 10.1007/s10822-011-9428-y
35. Fu L. L., Cheng Y., Liu B., Beclin-1: autophagic regulator and therapeutic target in cancer. The International Journal of Biochemistry & Cell Biology 2013 45 5 921 924 10.1016/j.biocel.2013.02.007
36. Akar U., Chaves-Reyez A., Barria M., Tari A., Sanguino A., Kondo Y., Kondo S., Arun B., Lopez-Berestein G., Ozpolat B., Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 2008 4 5 669 679 2-s2.0-48249087666
37. Shi C. S., Kehrl J. H., MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. Journal of Biological Chemistry 2008 283 48 33175 33182 2-s2.0-57749100267 10.1074/jbc.M804478200
38. Mencin A., Kluwe J., Schwabe R. F., Toll-like receptors as targets in chronic liver diseases. Gut 2009 58 5 704 720 2-s2.0-66349110620 10.1136/gut.2008.156307
39. Su L., Sun Y., Ma F., Lü P., Huang H., Zhou J., Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF- B activation and enhancing SOCS1 expression. Immunology Letters 2009 125 2 151 155 2-s2.0-68149124488 10.1016/j.imlet.2009.07.003
40. Scott M. J., Billiar T. R., β 2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes. Journal of Biological Chemistry 2008 283 43 29433 29446 2-s2.0-57649142987 10.1074/jbc.M803905200
41. Barth S., Glick D., Macleod K. F., Autophagy: assays and artifacts. Journal of Pathology 2010 221 2 117 124 2-s2.0-77952766891 10.1002/path.2694
42. Tanida I., Yamasaki M., Komatsu M., Ueno T., The FAP motif within human ATG7, an autophagy-related E1-like enzyme, is essential for the E2-substrate reaction of LC3 lipidation. Autophagy 2012 8 1 88 97 2-s2.0-84856487167 10.4161/auto.8.1.18339
43. Kaiser S. E., Mao K., Taherbhoy A. M., Yu S., Olszewski J. L., Duda D. M., Kurinov I., Deng A., Fenn T. D., Klionsky D. J., Schulman B. A., Noncanonical E2 recruitment by the autophagy E1 revealed by Atg7-Atg3 and Atg7-Atg10 structures. Nature Structural & Molecular Biology 2012 19 12 1242 1249 10.1038/nsmb.2415
44. Lo Y. L., Liu Y., Tsai J. C., Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Biomedicine & Pharmacotherapy 2013 67 4 261 267 10.1016/j.biopha.2012.12.002
45. Villar V. H., Vogler O., Martinez-Serra J., Ramos R., Calabuig-Farinas S., Gutierrez A., Barcelo F., Martín-Broto J., Alemany R., Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS ONE 2012 7 5 e37735 10.1371/journal.pone.0037735
46. Wu F., Shao Z. Y., Zhai B. J., Zhao C. L., Shen D. M., Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and bax protein. Ultrasound in Medicine and Biology 2011 37 1 151 159 2-s2.0-78649907143 10.1016/j.ultrasmedbio.2010.10.009
47. Leslie E. M., Deeley R. G., Cole S. P. C., Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology 2005 204 3 216 237 2-s2.0-17544368685 10.1016/j.taap.2004.10.012 (Pubitemid 40552845)
48. Lim S. C., Hahm K. S., Lee S. H., Oh S. H., Autophagy involvement in cadmium resistance through induction of multidrug resistance-associated protein and counterbalance of endoplasmic reticulum stress WI38 lung epithelial fibroblast cells. Toxicology 2010 276 1 18 26 2-s2.0-77955660031 10.1016/j.tox.2010.06.010